Search

Your search keyword '"Trinkaus K"' showing total 287 results
Start Over Author "Trinkaus K"
287 results on '"Trinkaus K"'

7. Alterations in the morphology of lamina cribrosa pores in glaucomatous eyes

Author

Tezel, G., Trinkaus, K., and Wax, M.B.

Subjects
Glaucoma -- Research, Health, Research
Abstract

Aims: To determine alterations which occur in the size and shape of lamina cribrosa (LC) pores in glaucomatous eyes over a period of time. Methods: Baseline and follow up optic [...]

Published
2004

14. Effekte eines mit Brain-Derived Neurotrophic Factor funktionalisierten pastenartigen Knochenzements auf die metaphysäre Heilung in einem neuen murinen osteoporotischen Frakturmodell

Author

Kauschke, V, additional, Schneider, M, additional, Jauch, A, additional, Schumacher, M, additional, Kampschulte, M, additional, Rohnke, M, additional, Henß, A, additional, Bamberg, C, additional, Trinkaus, K, additional, Gelinsky, M, additional, Heiß, C, additional, and Lips, KS, additional

Published
2019
Full Text
View/download PDF

16. Multicenter phase II trial of nab-paclitaxel and cisplatin (AP) followed by chemoradiation therapy (CRT) for locally advanced head and neck squamous cell carcinoma (HNSCC)

Author

Adkins, D., primary, Ley, J., additional, Gay, H.A., additional, Daly, M., additional, Jackson, R., additional, Rich, J., additional, Pipkorn, P., additional, Paniello, R.C., additional, Trinkaus, K., additional, Neupane, P., additional, Zevallos, J., additional, Thorstad, W., additional, and Oppelt, P., additional

Published
2018
Full Text
View/download PDF

23. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial(CME)(LOE Classification)

Author

Naismith, R.T., Piccio, L., Lyons, J.A., Lauber, J., Tutlam, N.T., Parks, B.J., Trinkaus, K., Song, S.K., and Cross, A.H.

Subjects
Adult, Male, B-Lymphocytes, Time Factors, Adolescent, Antibodies, Monoclonal, Gadolinium, Articles, Middle Aged, Magnetic Resonance Imaging, Severity of Illness Index, Drug Administration Schedule, Antibodies, Monoclonal, Murine-Derived, Disability Evaluation, Young Adult, Multiple Sclerosis, Relapsing-Remitting, Double-Blind Method, Humans, Immunologic Factors, Female, Rituximab, Aged, Follow-Up Studies
Abstract

B cells and the humoral immune system have been implicated in the pathogenesis of multiple sclerosis (MS). This study sought to evaluate the efficacy, safety, and tolerability of add-on therapy with rituximab, a monoclonal antibody that depletes circulating B cells, in subjects with relapsing MS with breakthrough disease defined by clinical and MRI activity (Class III evidence).Thirty subjects with a relapse within the past 18 months despite use of an injectable disease-modifying agent, and with at least 1 gadolinium-enhancing (GdE) lesion on any of 3 pretreatment MRIs, received rituximab administered at 375 mg/m(2) weekly x 4 doses. Three monthly posttreatment brain MRI scans were obtained beginning 12 weeks after the first infusion. Multiple Sclerosis Functional Composite (MSFC) and Expanded Disability Status Scale (EDSS) were obtained at baseline and throughout the posttreatment follow-up.GdE lesions were reduced after treatment with rituximab, with 74% of posttreatment MRI scans being free of GdE activity compared with 26% free of GdE activity at baseline (p0.0001). Median GdE lesions were reduced from 1.0 to 0, and mean number was reduced from 2.81 per month to 0.33 after treatment (88% reduction). MSFC improved as well (p = 0.02). EDSS remained stable.Rituximab add-on therapy was effective based upon blinded radiologic endpoints in this phase II study. In combination with standard injectable therapies, rituximab was well-tolerated with no serious adverse events. B-cell-modulating therapy remains a potential option for treatment of patients with relapsing MS with an inadequate response to standard injectable therapies.This study provides Class III evidence that add-on rituximab reduces gadolinium-enhancing brain lesions in multiple sclerosis.

Published
2010

27. Abstract OT2-6-12: A randomized pacebo-controlled phase II trial evaluating the effect of hedgehog inhibitor LDE225 on bone marrow disseminated tumor cells in women with early stage estrogen receptor negative and HER2 negative breast cancer

Author

Aft, R, primary, Weilbaecher, K, additional, Trinkaus, K, additional, Watson, M, additional, Bernadt, C, additional, Crouch, E, additional, Dahiya, N, additional, Ellis, M, additional, and Ma, C, additional

Published
2013
Full Text
View/download PDF

33. Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature

Author

Chawla, J.S., primary, Ghobadi, A., additional, Mosley, J., additional, Verkruyse, L., additional, Trinkaus, K., additional, Abboud, C.N., additional, Cashen, A.F., additional, Stockerl-Goldstein, K.E., additional, Uy, G.L., additional, Westervelt, P., additional, DiPersio, J.F., additional, and Vij, R., additional

Published
2011
Full Text
View/download PDF

50. Detection of Microdeletions and Amplifications in Primary Human Acute Myeloid Leukemia (AML) Genomes Using Ultradense Oligomer Tiling Path Arrays and Comparative Genomic Hybridization (CGH).

Author

Walter, Matthew J., primary, Ries, R. R., primary, Li, X. D., primary, Shannon, W. J., primary, Payton, J., primary, Bloomfield, C. D., primary, Mrozek, K., primary, Ruppert, A. S., primary, DiPersio, J., primary, Link, D., primary, Tomasson, M., primary, Graubert, T., primary, McLeod, H., primary, Devine, S., primary, Watson, M., primary, Heath, S., primary, Baty, J., primary, Trinkaus, K., primary, Armstrong, J., primary, Mardis, E., primary, Wilson, R., primary, Selzer, R., primary, Richmond, T., primary, Eis, P., primary, and Ley, T. J., primary

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results